Shares of Ultragenyx Pharmaceutical (RARE) surged 5.11% on November 11th, 2024, after a bullish analyst report from TD Cowen.
Analyst Yaron Werber maintained a Buy rating on Ultragenyx and reiterated his positive outlook on the biopharmaceutical company. While the exact details of the report were not disclosed, Werber's bullish stance seems to have fueled investor confidence in Ultragenyx, driving the stock price higher.
Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases. The company has several promising drug candidates in its pipeline, and Werber's report likely highlighted the potential for these therapies to drive future growth and profitability for the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.